Clinical Trials Browser

Active not recruiting × INDUSTRY × enzalutamide × Clear all

Metastatic Hormone Sensitive Prostate Cancer

NCT05901649 2026-04-13

ArtemisPRO

Active not recruiting

504 enrolled

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT03395197 2026-04-07

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

49 enrolled

Tumor-Agnostic

Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

Phase 3 Active not recruiting

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

Phase 1/2 Active not recruiting

174 enrolled

Genitourinary

Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Phase 3 Active not recruiting

439 enrolled

Genitourinary

Prostatic Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02319837 2025-07-08

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Phase 3 Active not recruiting

1,068 enrolled 20 charts 2 FDA

Genitourinary

Prostatic Neoplasms

Clinical Trials

China ARCHES

ArtemisPRO

TALAPRO-2

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

KEYNOTE-991

IMbrella B

SPLASH

CONTACT-02

PETRANHA

CDK4i

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

KEYNOTE-641

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)